Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study (Q47436578)

16 January 2018

title

Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study (English)

1 reference

16 January 2018

Hormone Replacement Therapy

main subject

1 reference

1 reference

4

1 reference

16 January 2018

Anne Tjønneland

1

object named as

Anne Tjønneland

1 reference

16 January 2018

5

Kim Overvad

1 reference

16 January 2018

2

Jane Christensen

1 reference

16 January 2018

Birthe Lykke Thomsen

3

object named as

Birthe L Thomsen

1 reference

16 January 2018

author name string

Marianne Ewertz

6

1 reference

16 January 2018

Lene Mellemkjaer

7

1 reference

16 January 2018

language of work or name

English

0 references

publication date

1 June 2004

1 reference

16 January 2018

published in

Cancer

1 reference

16 January 2018

volume

100

1 reference

16 January 2018

issue

11

1 reference

16 January 2018

page(s)

2328-2337

1 reference

16 January 2018

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20250

Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20250

Hormone replacement therapy regimens and breast cancer risk(1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20250

Hormone replacement therapy and breast carcinoma risk in Hispanic and non-Hispanic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20250

Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20250

More about: effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20250

Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20250

Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20250

Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20250

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20250

Trends in incidence rates of invasive lobular and ductal breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20250

Estrogen and progestin regulation of cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20250

Hormonal regulation of apoptosis in breast cells and tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20250

Relationship between long durations and different regimens of hormone therapy and risk of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20250

The risk of breast cancer following reproductive surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20250

Hysterectomy, oophorectomy in premenopause, and risk of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20250

Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20250

Breast cancer and hormone-replacement therapy: the Million Women Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20250

Prognosis of breast cancers detected in women receiving hormone replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20250

Estrogen and estrogen-progestin replacement therapy and risk of postmenopausal breast cancer in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20250

Hormone replacement therapy in relation to breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20250

Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20250

Increased incidence of small and well-differentiated breast tumours in post-menopausal women following hormone-replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20250

Important increase of invasive lobular breast cancer incidence in Geneva, Switzerland

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20250

Estradiol and progesterone regulate the proliferation of human breast epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20250

Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20250

Breast cancer risk associated with gynecologic surgery and indications for such surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20250

Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20250

7 January 2021

Validation of a semiquantitative food frequency questionnaire developed in Denmark.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20250

7 January 2021

Danish Breast Cancer Cooperative Group (DBCG). Structure and results of the organization.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20250

7 January 2021

Breast cancer among women from Gothenburg with regard to age, mortality and coexisting benign breast disease or leiomyoma uteri

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20250

7 January 2021

Identifiers

DOI

10.1002/CNCR.20250

1 reference

16 January 2018

1 reference

16 January 2018